Britain and America have forged a key commercial pact that will maintain zero levies on UK medicine exports going into the US market.
Key Provisions of the Deal
As part of the deal, the UK has pledged to increase funding on drugs through the public health system. This commitment ensures that tariffs on these vital products will be held at zero for a timeframe of three years.
This agreement follows previous threats to hike tariffs on patented drug imports, with figures floated up to double the cost.
"This agreement with the Britain strengthens the global environment for new treatments and brings much-needed balance to transatlantic drug exports," a statement noted.
Commercial Importance
Pharmaceuticals constitute one of the UK's biggest goods shipped to the America, which is by far the biggest market for major British pharmaceutical firms.
Trade data show that in the year to the end of the third quarter, the UK shipped pharmaceutical products worth £11.1bn to the US. This amount made up a significant portion of total UK exports in that timeframe.
"This agreement safeguards employment, boosts funding and sets the stage for the UK to emerge as a international leader for life sciences," the Business and Trade Secretary remarked.
Specific UK Commitments
The pact includes several key changes from the British government:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it deems new therapies to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a aim to raise total health service expenditure on medicines from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Payback Limit: The sum pharmaceutical firms must refund to the NHS to prevent overspending will be restricted at fifteen percent. In the past, repayments exceeded twenty percent.
Recent Tensions
The pact follows a protracted row between the pharmaceutical industry and the British authorities over spending levels and regulatory access.
The disagreement were intensified by claims that American consumers were charged significantly more for the equivalent treatments than patients in the Britain and the EU.
Over the last 18 months, several significant pharmaceutical investments in the UK have been delayed or scrapped, while substantial investments have been pledged toward US facilities.
One official stated that the NHS needed to invest a greater share on medicines, noting that its budget allocation on drugs had declined as a share of its overall budget over the previous ten-year period.
